NCT06308822 2026-03-18Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled 9 charts